Cytoskeletal active agents for glaucoma therapy
US6586425B2 · kind B2 · utility
71Cited by
6References
19Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 29, 2001 |
| Grant date | Jul 1, 2003 |
| Priority date | — |
| Expiry date | Jan 29, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/551
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for the treatment of glaucoma are provided by the present invention. The compounds described cause a perturbation of the actin cytoskeleton in the trabecular meshwork or the modulation of its interactions with the underlying membrane. Perturbation of the cytoskeleton and the associated adhesions reduces the resistance of the trabecular meshwork to fluid flow and thereby reduces intraocular pressure.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.